The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia

Neuropsychopharmacology

Volumn 31, Issue 5, 2006, Pages 1027-1035

  Gründer, Gerhard ^a,b   Landvogt, Christian ^a   Vernaleken, Ingo ^a,b   Buchholz, Hans Georg ^a   Ondracek, Jasmin ^a   Siessmeier, Thomas ^a   Härtter, Sebastian ^a   Schreckenberger, Mathias ^a   Stoeter, Peter ^a   Hiemke, Christoph ^a   Rösch, Frank ^a   Wong, Dean F ^c   Bartenstein, Peter ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

18F fallypride; Clozapine; D2 receptor occupancy; Positron emission tomography; Schizophrenia

Indexed keywords

CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; FALLYPRIDE F 18; FLUORINE 18; NORCLOZAPINE; RADIOLIGAND; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CORPUS STRIATUM; DRUG BLOOD LEVEL; DRUG DOSE; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; FEMALE; HUMAN; INFERIOR TEMPORAL CORTEX; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MAXIMUM ATTAINABLE RECEPTOR OCCUPANCY; MEASUREMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; TEMPORAL CORTEX;

ADULT; ANTIPSYCHOTIC AGENTS; BENZAMIDES; BINDING, COMPETITIVE; CLOZAPINE; CORPUS STRIATUM; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PYRROLIDINES; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SCHIZOPHRENIA; TEMPORAL LOBE;

EID: 33646137570     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300931     Document Type: Article

References (46)

1. Bigliani V, Mulligan RS, Acton PD, Ohlsen RI, Pike VW, Ell PJ et al (2000). Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study. Psychopharmacology 150: 132-140.
2. Bressan RA, Erlandsson K, Jones HM, Mulligan RS, Ell PJ, Pilowsky LS (2003). Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study. J Clin Psychopharmacol 23: 5-14.
3. Brown RM, Crane AM, Goldman PS (1979). Regional distribution of monoamines in the cerebral cortex and subcortical structures of the rhesus monkey: concentrations and in vivo synthesis rates. Brain Res 168: 133-150.
4. Buchholz H-G, Siessmeier T, Landvogt C, Vernaleken I, Schirrmacher R, Schreckenberger M et al (2004). Stereotactic normalisation of BP images of D2-receptor ligand 18F-desmethoxyfallypride using ligand-specific template and SPM. Neuroimage 22(Suppl 2): T105.
5. Erlandsson K, Bressan RA, Mulligan RS, Ell PJ, Cunningham VJ, Pilowsky LS (2003). Analysis of D2 dopamine receptor occupancy with quantitative SPET using the high-affinity ligand [123I]epidepride: resolving conflicting findings. Neuroimage 19: 1205-1214.
6. Farde L, Nordström AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992). Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49: 538-544.
7. 2 receptor increase in PET study of schizophrenia (letter). Arch Gen Psychiatry 44: 671-672.
8. Garris PA, Wightman RM (1994). Different kinetics govern dopaminergic transmission in the amygdala, prefrontal cortex, and striatum: an in vivo voltammetric study. J Neurosci 14: 442-450.
9. Gefvert O, Lundberg T, Wieselgren IM, Bergstrom M, Langstrom B, Wiesel F et al (2001). D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol 11: 105-110.
10. Goldsmith SK, Shapiro RM, Joyce JN (1997). Disrupted pattern of D2 dopamine receptors in the temporal lobe in schizophrenia. A postmortem study. Arch Gen Psychiatry 54: 649-658.
11. Gründer G, Carlsson A, Wong DF (2003a). Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 60: 974-977.
12. 18F]desmethoxyfallypride. J Nucl Med 44: 109-116.
13. Gurevich EV, Bordelon Y, Shapiro RM, Arnold SE, Gur RE, Joyce JN (1997). Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch Gen Psychiatry 54: 225-232.
14. Halldin C, Farde L, Hogberg T, Mohell N, Hall H, Suhara T et al (1995). Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. J Nucl Med 36: 1275-1281.
15. Hietala J, Syvalahti E, Vuorio K, Nagren K, Lehikoinen P, Ruotsalainen U et al (1994). Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch Gen Psychiatry 51: 116-123.
16. Joyce JN (2001). D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period. Synapse 40: 137-144.
17. Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000a). Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157: 514-520.
18. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P (2000b). A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 57: 553-559.
19. Kapur S, Zipursky RB, Remington G (1999). Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156: 286-293.
20. Kessler RM, Ansari SM, Li R, Dawant B, Lee M, Meltzer HY (2002). Occupancy of striatal and extrastriatal dopamine D2 receptors by atypical antipsychotic drugs. J Nucl Med 43(Suppl): 15.
21. Kronig MH, Munne RA, Szymanski S, Safferman AZ, Pollack S, Cooper T et al (1995). Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry 152: 179-182.
22. Lammertsma AA, Hume SP (1996). Simplified reference tissue model for PET receptor studies. Neuroimage 4: 153-158.
23. Lidow MS, Elsworth JD, Goldman-Rakic PS (1997). Down-regulation of the D1 and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs. J Pharmacol Exp Ther 281: 597-603.
24. Mukherjee J, Christian BT, Dunigan KA, Shi B, Narayanan TK, Satter M et al (2002). Brain imaging of 18F-fallypride in normal volunteers: blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. Synapse 46: 170-188.
25. Mukherjee J, Christian BT, Narayanan TK, Shi B, Mantil J (2001). Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride. Neuropsychopharmacology 25: 476-488.
26. Mukherjee J, Yang ZY, Das MK, Brown T (1995). Fluorinated benzamide neuroleptics - III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxy-benzamide as an improved dopamine D-2 receptor tracer. Nucl Med Biol 22: 283-296.
27. Nordström AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G (1995). D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 152: 1444-1449.
28. Olsson H, Farde L (2001). Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy - a simulation study based on experimental data. Neuroimage 14: 936-945.
29. Olsson H, Halldin C, Farde L (2004). Differentiation of extrastriatal dopamine D2 receptor density and affinity in the human brain using PET. Neuroimage 22: 794-803.
30. Pehek EA (1999). Comparison of effects of haloperidol administration on amphetamine-stimulated dopamine release in the rat medial prefrontal cortex and dorsal striatum. J Pharmacol Exp Ther 289: 14-23.
31. Perry PJ, Miller DD, Arndt SV, Cadoret RJ (1991). Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 148: 231-235.
32. Pilowsky LS, Mulligan RS, Acton PD, Ell PJ, Costa DC, Kerwin RW (1997). Limbic selectivity of clozapine. Lancet 350: 490-491.
33. Potkin SG, Bera R, Gulasekaram B, Costa J, Hayes S, Jin Y et al (1994). Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 55(Suppl B): 133-136.
34. Riva MA, Tascedda F, Lovati E, Racagni G (1997). Regulation of NMDA receptor subunit messenger RNA levels in the rat brain following acute and chronic exposure to antipsychotic drugs. Brain Res Mol Brain Res 50: 136-142.
35. Seeman P (2002). Atypical antipsychotics: mechanism of action. Can J Psychiatry 47: 27-38.
36. Siessmeier T, Zhou Y, Buchholz H-G, Landvogt C, Vernaleken I, Piel M et al (2005). Comparison of parametric methods for the analysis of PET studies with D2 receptor ligands of different affinities. J Nucl Med 46: 964-972.
37. Suhara T, Okauchi T, Sudo Y, Takano A, Kawabe K, Maeda J et al (2002a). Clozapine can induce high dopamine D(2) receptor occupancy in vivo. Psychopharmacology (Berl) 160: 107-112.
38. Suhara T, Okubo Y, Yasuno F, Sudo Y, Inoue M, Ichimiya T et al (2002b). Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch Gen Psychiatry 59: 25-30.
39. Takano A, Suhara T, Ikoma Y, Yasuno F, Maeda J, Ichimiya T et al (2004). Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. Int J Neuropsychopharmacol 7: 19-26.
40. Talvik M, Nordström AL, Nyberg S, Olsson H, Halldin C, Farde L (2001). No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457. Am J Psychiatry 158: 926-930.
41. Talvik M, Nordstrom AL, Olsson H, Halldin C, Farde L (2003). Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C]FLB 457. Int J Neuropsychopharmacol 6: 361-370.
42. Tuppurainen H, Kuikka J, Viinamaki H, Husso-Saastamoinen M, Bergstrom K, Tiihonen J (2003). Extrastriatal dopamine D 2/3 receptor density and distribution in drug-naive schizophrenic patients. Mol Psychiatry 8: 453-455.
43. Vernaleken I, Siessmeier T, Buchholz H-G, Härtter S, Hiemke C, Stoeter P et al (2004). High striatal occupancy of D2-like dopamine receptors by amisulpride in brain of patients with schizophrenia. Int J Neuropsychopharmacol 7: 421-430.
44. Weigmann H, Härtter S, Mehrlein S, Kiefer W, Krämer G, Dannhardt G et al (2001). Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column-switching high performance liquid chromatography. J Chromatogr B Sci 759: 63-71.
45. Xiberas X, Martinot JL, Mallet L, Artiges E, Canal M, Loc'h C et al (2001). In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. J Clin Psychopharmacol 21: 207-214.
46. Yasuno F, Suhara T, Okubo Y, Sudo Y, Inoue M, Ichimiya T et al (2004). Low dopamine d(2) receptor binding in subregions of the thalamus in schizophrenia. Am J Psychiatry 161: 1016-1022.